Scisparc Ltd (SPRC) - News Archive

Showing 9 of 29 results.

SciSparc's Breakthrough Treatment for Autism Spectrum Disorder Commences Clinical Trial, Offering Hope for Transformative Results

SciSparc, a leading pharmaceutical company dedicated to developing innovative treatments for neurological disorders, announced today the availability of their SCI-210 treatment at a clinical site for a groundbreaking cl...

Feb 29, 2024 • Major Pharmaceutical Preparations Industry Clinical Study ClinicalTrial

The Dawn of a New Therapeutic Era: SciSparc Spearheads SCI-210 Clinical Trial in Autistic Children.

The strides being taken in an authentic and innovative experimental approach to addressing the challenges of Autism Spectrum Disorder (ASD) come forth with the announcement by SciSparc Ltd of the initiation of patient r...

Jan 29, 2024 • Major Pharmaceutical Preparations Industry Clinical Study Clinicalstudy

SciSparc Announces $20 Million Standby Equity Purchase Agreement, Paving the Way for Growth and Expansion

SciSparc Ltd., a specialty clinical-stage pharmaceutical company based in Tel Aviv, Israel, has recently made a significant announcement regarding its plans for future growth and development. In a press release, the com...

Jan 24, 2024 • Major Pharmaceutical Preparations Industry Contract standbyequitypurchaseagreement

SciSparc Ltd, a specialty clinical-stage pharmaceutical company based in Tel Aviv, Israel, recently made a significant move in its acquisition process of a prominent vehicle importer company in Israel On January 19, 2024, SciSparc announced that it had entered into a bridge loan agreement with the target company, providing them with a bridge loan of $14 million

SciSparc Ltd., a specialty clinical-stage pharmaceutical company based in Tel Aviv, Israel, recently made a significant move in its acquisition process of a prominent vehicle importer company in Israel. On January 19, 2...

Jan 19, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition

SciSparc Limited Embarks on a New Era with Acquisition of Leading Israeli Vehicle Importer and Revised Ownership Structure

SciSparc Announces Acquisition of Leading Vehicle Importer in Israel and Revised Ownership StructureTEL AVIV, Israel, Dec. 07, 2023 - SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focus...

Dec 7, 2023 Contract Letter of Intent

SciSparc's CBD-Enhanced Therapy: A Breakthrough for Children with Autism Spectrum Disorder

New Hope for Children: SciSparc s CBD-Enhanced Solution for Autism Spectrum Disorder Shows Promising ResultsTEL AVIV, Israel, Nov. 24, 2023 - SciSparc Ltd. (Nasdaq: SPRC), a leading specialty clinical-stage pharmaceutic...

Nov 24, 2023 Clinical Study Autism

SciSparc Accelerates Revenue Growth and Explores Pharmaceutical Expansion in Groundbreaking Merger

SciSparc, a prominent pharmaceutical company, has recently announced the signing of a non-binding Letter of Intent (LOI) with a leading vehicle importer company in Israel. This strategic move aims to propel SciSparc tow...

Nov 22, 2023 Contract Merger

Scisparc Ltd Announces Reverse Share Split to Optimize Shareholder Value

Scisparc Ltd Announces 1-for-26 Reverse Share SplitFollowing the recent press release by Scisparc Ltd, it has been announced that the company will soon undergo a 1-for-26 reverse share split. This move comes as part of...

Sep 27, 2023 Shares ReverseShareSplit

SciSparc Ltd. Announces Reverse Share Split to Drive Growth and Enhance Shareholder Value

Tel Aviv, Israel - September 20, 2023: SciSparc Ltd. (Nasdaq: SPRC), a prominent clinical-stage pharmaceutical company focusing on the development of therapies for disorders and rare diseases of the central nervous syst...

Sep 20, 2023 Shares ReverseSplit